The Society for Immunotherapy of Cancer (SITC) hosted Session 207c during the 39th Annual Meeting & Pre-Conference Programs on Saturday, November 9, 2024. Available here are the presentation slides and video from “Session 207c: Biomarkers Guiding Design of T Cell Therapies” as permitted by presenters.
James Yang, MD – The National Cancer Institute
Simon Turcotte, MD, MSc, FRCSC – Universite de Montreal
Due to their complexity, designing cell-based immunotherapy trials to integrate with other therapies, be efficiently implemented and then be quickly evaluated for efficacy is difficult. New technologies can assist in these goals. This session looks at how some of those methods can accelerate the identification of tumor from which tumor-reactive T cells can be expanded ex-vivo, the selection of patients more likely to respond, and then provide early endpoints of treatment efficacy. Because the common epithelial cancers result in the vast majority of cancer deaths, the application of these approaches towards tumor infiltrating lymphocyte therapy for these cancers will be highlighted.
To view the entire program schedule (including presenter permission to post) please click here.
01:31:19